Keeping it real... Anti-Parasitic Drug Eliminates

New Post Public Reply Private Reply Replies (0) Message Board
Rubraquercus
745
Keeping it real...

[COVID-19 Update] Anti-Parasitic Drug Eliminates Coronavirus in Animal Lungs; New Methods to Safely Inactivate SARS-CoV-2 Discovered
Coronavirus found in animals' lungs has been cured by an anti-parasitic drug as claimed by a new study. According to The New York Times' latest report, South Korea's Daewoong Pharmaceutical revealed that tests involving an anti-parasitic drug have proven to be effective in fighting the coronavirus in animals.
Also Read: [Coronavirus: COVID-19 Spreading Since August in Wuhan? Satellite Images and Internet Searches Back up Claims](https://www.techtimes.com/articles/250201/20200609/coronavirus-covid-19-spreading-since-august-in-wuhan-sat
ellite-images-and-internet-searches-back-up-claims.htm)
![Anti-Parasitic Drug Effective Against Coronavirus In Animal Tests: New Methods to Safely Inactive SARS-CoV-2, Revealed by Scientists](bundle://article1.jpg "Anti-Parasitic Drug Effective Against Coronavirus In Animal Tests: New Methods to Safely Inactive SARS-CoV-2, Revealed by Scientists"
(Photo : National Cancer Institute on Unsplash)Anti-Parasitic Drug Effective Against Coronavirus In Animal Tests: New Methods to Safely Inactive SARS-CoV-2, Revealed by Scientists
It was reported that the anti-parasitic drug of South Korea's Daewoong Pharmaceutical called "niclosamide" eliminated the novel coronavirus lingering in the lungs of the animals used in their tests. The global impact of the novel coronavirus has pushed drugmakers around the world to quickly develop treatments for COVID-19 which has now killed more than 400,000 people around the globe since its first appearance in China late last year.
Also Read: [\[COVID-19 Update\] Heartburn Drug Can Fight Moderately Severe Coronavirus Cases; Vaccine May Take 10-15 Years Experts Say](https://www.techtimes.com/articles/250182/20200608/covid-19-update-heartburn-drug-can-fight-moderately-seve
re-coronavirus-cases-vaccine-may-take-10-15-years-experts-say.htm)
Niclosamide, an anti-parasite drug, is a wide ranging antiviral that was already known to inhibit SARS-CoV replication.It has also been shown to inhibit viral replication of COVID19 & render the viral pathogen noninfectious.This is extremely promising along with HCQ + zpak. pic.twitter.com/eXZLLornhJ — Michael James Coudrey (@MichaelCoudrey) April 5, 2020The Korean pharmaceutical company said that the results of the study showed that the anti-parasitic drug has eliminated the viral disease found in the tissues of ferrets' lungs, preventing the inflammation. Daewoong Pharmaceutical said that it plans to start human clinical trials by July.
Anti-parasitic drug effective against coronavirus in animal tests; New methods to safely inactive SARS-CoV-2, revealed by scientists
Niclosamide is currently being tested by three other companies around the world as a treatment for the novel coronavirus. However, the report stated that South Korea's Daewoong Pharmaceutical is not the only company that offers the anti-parasitic drug in a form that is not given orally.
(Photo : CDC on Unsplash)Anti-Parasitic Drug Effective Against Coronavirus In Animal Tests: New Methods to Safely Inactive SARS-CoV-2, Revealed by Scientists
"Based on the positive outcome of the animal test, we plan to complete human trials and get approval of the COVID-19 treatment drug by the end of this year," said Daewoong Pharma's CEO Jeon Seng-ho.
The report stated that human trials of several other drugs have not shown conclusive results. Currently, there is no effective treatment yet for COVID-19. Within the three trading days after the company's announcement last week, the shares of Daewoong Pharma jumped 48.2% as of Tuesday, June 9.
Meanwhile, Fox News has reported that new methods to safely inactivate SARS-CoV-2, the virus that causes COVID-19, were revealed by scientists. The study led by virologists at the Institute for Biomedical Sciences at Georgia State University was peer-reviewed and published in the Journal Viruses. It explained how to inactivate the virus to achieve a safe study of the infected cells.
"Importantly, the study defines specific methods that fully inactivate the virus, that is make it non-infectious, in ways compatible with further scientific analysis," said Professor Christopher Basler of the Institute for Biomedical Sciences.
"This allows researchers to study the proteins and genes of the virus and how the infected host responds to infection outside of high containment. Confirming that such analyses can be done safely, with no risk of infection, will increase the rate of discovery about the virus and COVID-19," he added.
[Also Read: Russia's NEW COVID-19 Drug Cures 'Excessive Inflammation' of Virus Patients](https://www.techtimes.com/articles/250202/20200609/russias-new-covid-19-drug-cures-excessive-inflammation-of-virus-patients.htm)
3

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Q32 Bio Eyes New Horizons with Bempikibart's Potentials

Updated Category News Views 69

Q32 Bio Steers Forward: New Insights from Chief Results Today's update isn't just another quarterly snooze-fest—it’s a nudge in a crucial direction for Q32 Bio (NASDAQ:QTTB). After a bold brush with the European Academy of Dermatology and Venereology (EADV) Congress 2026, the company laid out a plan and a half, showing its hand with bempikibart for alopecia areata...

Continue Reading
First Industrial Declares Regular Dividend Amid Growth Insights

Updated Category News Views 116

Dividend Declaration Reflects Confidence First Industrial Realty Trust, folks, just put another office stamp on their ongoing reliability quest—and I'm talking dividends. They're shelling out a tidy $0.50 per share for Q4 2026, with stockholders due to see the cash on January 19, 2027. That's like clockwork precision, showing a steadiness in what some call the unruly...

Continue Reading
Toufayan's Sourdough Pita: A Century-Old Recipe Revival

Updated Category News Views 23

Crafting Tradition in Modern Times Ever see a family business stick to its roots despite the whirlwind of fleeting trends? Step aside, because Toufayan isn’t just baking bread—they're pulling a Houdini act, bringing a recipe out of the past and into our grocery aisles. By launching their Simply Sourdough pita, these folks are banking on good ol’ nostalgia and...

Continue Reading
Japan's RWE Market Transformation: TXP's Insightful Whitepaper

Updated Category News Views 55

Unraveling the Real-World Evidence Landscape in Japan The folks at TXP Medical just dropped a bombshell of a whitepaper that'll have Medical Affairs departments buzzing. Imagine waking up to a market that's exploding by over 500% in just a decade—yeah, I'm talking about the EMR-derived data market in Japan. These guys are saying it's gonna shoot from ¥3.9 billion in...

Continue Reading
Askey & Icom Team Up: Trading Airwaves for Partnerships

Updated Category News Views 28

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...

Continue Reading
Acuity Analytics Charts Ambitious AI-Driven Future

Updated Category News Views 128

The New Era at Acuity Analytics Has Begun Isn't it something when a company decides to shake things up in such a daring way? Acuity Analytics just gave the financial sector a reason to sit up and pay attention. They've brought in Jon O'Donnell as the new Chief Executive Officer, a move that's got the city talking. O'Donnell is no rookie; he's a former IBM heavyweight and...

Continue Reading
A Journey Through Mongolia's Wilderness and Self-Discovery

Updated Category News Views 57

A Late-Life Adventure Without Borders We all hit that age where adventure seems just a memory—until something shakes us from our slumber, just like Betsy Cooksey’s wild ride into Mongolia. At an age when most tether their dreams to sunlit porches and grandkids' photos, Cooksey grabbed life by the reins. First, though, we gotta talk about the absolute gamble she took....

Continue Reading
Lone Star's Debrief IQ: Revamping Military Training

Updated Category News Views 20

A Milestone for Military Pilot Training In the grand scheme of military pilot training, Debrief IQ from Lone Star Analysis is making waves. Apparently, they're shaving off a hefty 35 minutes of the grind instructors typically endure post-training sessions. I bet the flight schools are letting out a collective sigh of relief. Years of Frustration Handled by AI So, what's...

Continue Reading
Tigo Energy Faces Legal Heat Over Fraud Allegations

Updated Category News Views 142

Tigo Energy's Legal Battle Heats Up If you haven't been paying attention, it’s time to get your eyes on Tigo Energy (NASDAQ: TYGO). The company is now in the hot seat with a securities fraud lawsuit that's got investors on edge. This isn’t just a minor squabble; we're talking about allegations that could shake the ground beneath its share price. The Claims and...

Continue Reading
AI Shift: From Tech Marvels to Practical Uses

Updated Category News Views 80

A New Chapter in the AI Narrative Take a seat, folks, because we're watching AI swing from showy tech to something as plain as plumbing infrastructure. Imagine models that once cost bundles per token now going for peanuts. We're talking a nosedive from $37.50 to a mere 18 cents. It’s a seismic shift, steering the conversation from 'Are they the best models?' to 'How...

Continue Reading

Top 5 Most Recently Viewed Articles

Angel Oak Financial Strategies Hits New High of $13.35

Updated Category News Views 193

Angel Oak Financial Strategies Reaches New Heights Shares of Angel Oak Financial Strategies (FINS) have achieved a remarkable milestone by reaching a 52-week high, trading at an impressive $13.35. This significant growth is a testament to the company’s strong performance in the financial market. Investors are celebrating as they witness this increase, which stands as a...

Continue Reading
Indonesian Market Update: IDX Composite Index Drop Analyzed

Updated Category News Views 263

Overview of the Indonesian Stock Market's Recent Performance On a recent trading day, the Indonesian stock market experienced a notable decline, with the IDX Composite Index sliding 1.08%. This downtrend was largely influenced by losses in significant sectors such as Financials, Infrastructure, and Agriculture. Understanding these dynamics is essential for investors and...

Continue Reading
Eagle Bancorp Teams Up for Major Financial Conference in November

Updated Category News Views 103

Eagle Bancorp to Feature at Notable Financial Conference Eagle Bancorp, Inc. (NASDAQ: EGBN), the prominent holding company of EagleBank, is gearing up to participate in an influential financial event. This conference, the Piper Sandler East Coast Financial Services Conference, takes place over several days, offering a platform for significant discussions within the...

Continue Reading
Breathe Drops: A Game-Changer for Respiratory Wellness

Updated Category News Views 295

Introducing Breathe Drops: A Revolutionary Wellness Solution In the ever-evolving world of wellness, Breathe is thrilled to unveil its latest product, Breathe Drops. This unique formula aims to enhance lung health and respiratory wellness by harnessing the power of carefully selected natural ingredients. Designed for individuals seeking natural wellness solutions, Breathe...

Continue Reading
Keros Therapeutics to Showcase Innovations at Health Conference

Updated Category News Views 132

Keros Therapeutics to Showcase Innovations at Health Conference During an important upcoming event, Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company, will highlight its ongoing commitment to developing novel therapeutics aimed at treating conditions tied to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) protein...

Continue Reading